Stock News

Salient Capital Advisors Decreased By $11.00 Million Its Western Gas Equity Partners (WGP) Position; Recro Pharma, Inc. (REPH) Covered By 8 Bulls

Among 8 analysts covering Recro Pharma (NASDAQ:REPH), 8 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Recro Pharma had 14 analyst reports since August 25, 2015 according to SRatingsIntel. Piper Jaffray initiated Recro Pharma, Inc. (NASDAQ:REPH) rating on Monday, December 19. Piper Jaffray has “Overweight” rating and $12 target. As per Thursday, November 9, the company rating was maintained by Roth Capital. The company was initiated on Wednesday, September 2 by H.C. Wainwright. H.C. Wainwright initiated it with “Buy” rating and $14 target in Tuesday, November 24 report. The firm has “Buy” rating given on Monday, October 3 by Brean Capital. The rating was upgraded by Zacks on Tuesday, August 25 to “Hold”. Roth Capital maintained the stock with “Buy” rating in Thursday, July 20 report. The stock of Recro Pharma, Inc. (NASDAQ:REPH) has “Buy” rating given on Monday, August 29 by Janney Capital. Roth Capital maintained Recro Pharma, Inc. (NASDAQ:REPH) on Monday, July 31 with “Buy” rating. Roth Capital initiated the shares of REPH in report on Friday, September 16 with “Buy” rating. See Recro Pharma, Inc. (NASDAQ:REPH) latest ratings:

09/11/2017 Broker: Roth Capital Rating: Buy New Target: $18.0 Maintain
31/07/2017 Broker: Roth Capital Rating: Buy New Target: $20.0000 Maintain
25/07/2017 Broker: Piper Jaffray Rating: Buy New Target: $11.0000 Maintain
20/07/2017 Broker: Roth Capital Rating: Buy New Target: $20.0000 Maintain

Salient Capital Advisors Llc decreased Western Gas Equity Partners (WGP) stake by 6.62% reported in 2017Q3 SEC filing. Salient Capital Advisors Llc sold 268,346 shares as Western Gas Equity Partners (WGP)’s stock declined 5.04%. The Salient Capital Advisors Llc holds 3.78M shares with $155.83M value, down from 4.05M last quarter. Western Gas Equity Partners now has $9.22 billion valuation. The stock increased 0.19% or $0.08 during the last trading session, reaching $42.12. About 276,612 shares traded or 62.07% up from the average. Western Gas Equity Partners, LP (NYSE:WGP) has risen 3.31% since January 14, 2017 and is uptrending. It has underperformed by 13.39% the S&P500.

Investors sentiment increased to 1.23 in 2017 Q3. Its up 0.11, from 1.12 in 2017Q2. It improved, as 10 investors sold WGP shares while 30 reduced holdings. 13 funds opened positions while 36 raised stakes. 39.37 million shares or 2.95% more from 38.24 million shares in 2017Q2 were reported. Tortoise Cap Ltd Liability stated it has 0.32% of its portfolio in Western Gas Equity Partners, LP (NYSE:WGP). Glenmede Tru Na has invested 0.02% of its portfolio in Western Gas Equity Partners, LP (NYSE:WGP). Cushing Asset Mngmt Ltd Partnership has invested 1.25% of its portfolio in Western Gas Equity Partners, LP (NYSE:WGP). Arrowstreet Cap L P, Massachusetts-based fund reported 29,100 shares. Alps Advsr owns 27,463 shares. Parkside Natl Bank Trust accumulated 25,030 shares. Morgan Stanley holds 0.01% or 645,614 shares in its portfolio. Goldman Sachs Gru reported 0.01% in Western Gas Equity Partners, LP (NYSE:WGP). Sterling Capital Mngmt, North Carolina-based fund reported 4,983 shares. Moreover, Spirit Of America Mgmt has 0.83% invested in Western Gas Equity Partners, LP (NYSE:WGP). Clearbridge Investments Ltd Liability Co, New York-based fund reported 10,250 shares. Center Coast Cap Advisors LP holds 0.88% or 864,477 shares in its portfolio. Cohen & Steers accumulated 148,844 shares. Tph Asset Mngmt Lc has invested 3.12% of its portfolio in Western Gas Equity Partners, LP (NYSE:WGP). Fort Washington Invest Advsrs Inc Oh reported 42,770 shares.

Salient Capital Advisors Llc increased Kinder Morgan Inc Del (NYSE:KMI) stake by 480,271 shares to 6.00 million valued at $115.01M in 2017Q3. It also upped Pembina Pipeline Corp (NYSE:PBA) stake by 11,340 shares and now owns 400,212 shares. Shell Midstream Partners LP was raised too.

Analysts await Western Gas Equity Partners, LP (NYSE:WGP) to report earnings on February, 28. They expect $0.44 earnings per share, up 12.82% or $0.05 from last year’s $0.39 per share. WGP’s profit will be $96.33 million for 23.93 P/E if the $0.44 EPS becomes a reality. After $0.44 actual earnings per share reported by Western Gas Equity Partners, LP for the previous quarter, Wall Street now forecasts 0.00% EPS growth.

Among 19 analysts covering Western Gas Equity Partners (NYSE:WGP), 8 have Buy rating, 0 Sell and 11 Hold. Therefore 42% are positive. Western Gas Equity Partners had 31 analyst reports since August 3, 2015 according to SRatingsIntel. The rating was maintained by RBC Capital Markets with “Buy” on Sunday, October 29. RBC Capital Markets maintained it with “Buy” rating and $53.0 target in Sunday, August 20 report. The firm earned “Buy” rating on Monday, September 25 by RBC Capital Markets. The company was downgraded on Thursday, August 6 by Zacks. The stock has “Market Perform” rating by Wells Fargo on Monday, January 18. On Thursday, March 17 the stock rating was downgraded by Credit Suisse to “Neutral”. The firm has “Market Perform” rating by Wells Fargo given on Friday, January 15. Wunderlich downgraded Western Gas Equity Partners, LP (NYSE:WGP) on Wednesday, January 20 to “Hold” rating. The company was initiated on Friday, June 17 by MUFG. The rating was maintained by Deutsche Bank with “Hold” on Tuesday, October 20.

Recro Pharma, Inc., a specialty pharmaceutical company, engages in developing non-opioid products for the treatment of acute pain primarily in the United States. The company has market cap of $169.66 million. The Company’s lead product candidate includes injectable meloxicam, which completed pivotal Phase III clinical trials for the treatment of post-operative pain. It currently has negative earnings. The firm also provides Dex-IN, an intranasal formulation of dexmedetomidine that is in development stage for treating post-operative pain and peri-procedural pain; and Fadolmidine, alpha-2 agonist product for use in treating neuropathic pain.

Investors sentiment decreased to 1.65 in Q3 2017. Its down 0.56, from 2.21 in 2017Q2. It dropped, as 7 investors sold Recro Pharma, Inc. shares while 10 reduced holdings. 5 funds opened positions while 23 raised stakes. 9.63 million shares or 4.72% less from 10.10 million shares in 2017Q2 were reported. Panagora Asset Mngmt accumulated 0% or 8,144 shares. Deerfield Mgmt Co, a New York-based fund reported 1.90 million shares. Bnp Paribas Arbitrage reported 0% in Recro Pharma, Inc. (NASDAQ:REPH). Northern Tru Corporation owns 141,841 shares for 0% of their portfolio. Grp Incorporated reported 9,133 shares stake. Goldman Sachs Gru stated it has 0% in Recro Pharma, Inc. (NASDAQ:REPH). State Of Wisconsin Inv Board holds 0% of its portfolio in Recro Pharma, Inc. (NASDAQ:REPH) for 11,000 shares. Legal General Grp Pcl holds 2,026 shares. California Public Employees Retirement Systems invested 0% in Recro Pharma, Inc. (NASDAQ:REPH). Bank Of Montreal Can stated it has 4,328 shares. Renaissance Tech Limited Liability Corp accumulated 0% or 98,900 shares. Barclays Pcl accumulated 590 shares. Meeder Asset Mngmt holds 973 shares or 0% of its portfolio. Rhumbline Advisers holds 15,411 shares. Broadfin Cap Ltd Limited Liability Company holds 4.12% or 3.10 million shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Leave a Reply

Your email address will not be published. Required fields are marked *